Second-Line Immunotherapy in Advanced Non-Driver NSCLC – Targeted Oncology
OncLive |
Second-Line Immunotherapy in Advanced Non-Driver NSCLC
Targeted Oncology Benjamin P. Levy, MD: We now have 3 drug approvals for second-line non–small cell lung cancer, with immunotherapy. We’ve got single-agent pembrolizumab, single-agent nivolumab, and single-agent atezolizumab, all showing superior outcomes when compared … Shifting NSCLC Landscape Creates Confusion for PD-1/Chemo ComboOncLive |
|
Lonza Opens World’s Largest Dedicated Cell And Gene Therapy Manufacturing Facility
Pharmaceutical Processing Lonza opened the world’s largest dedicated cell and gene therapy facility, which was built in anticipation of the rising demand from developers of cell and gene therapies—believed to be the next era in medicine—and with the mission of enabling them … |